Mark Wickens
Impact in
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- Inflammatory mediators and NSAID effects 3
- Pharmacology and Obesity Treatment 2
-
- Antiplatelet Therapy and Cardiovascular Diseases 4
- Co-authors
- Michael Friedländer (3 shared papers)James Carmichael (3 shared papers)Jeffrey N. Weitzel (2 shared papers)M. William Audeh (2 shared papers)Rita K. Schmutzler (2 shared papers)Andrew Tutt (2 shared papers)Ursula A. Matulonis (3 shared papers)Katherine M. Bell‐McGuinn (2 shared papers)
- Journals
- European Heart Journal (2 papers)The Lancet (2 papers)British Journal of Clinical Pharmacology (1 paper)Journal of the American College of Cardiology (1 paper)Circulation (1 paper)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Mark Wickens
14 papers receiving 4.7k citations
Mark Wickens's Hit Papers
Peers
Comparison fields: 5 of 96
- Oncology 2.6k
- Internal Medicine 286
- Reproductive Medicine 493
- Cardiology and Cardiovascular Medicine 985
- Cancer Research 658
Countries citing papers authored by Mark Wickens
This map shows the geographic impact of Mark Wickens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wickens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wickens more than expected).
Fields of papers citing papers by Mark Wickens
This network shows the impact of papers produced by Mark Wickens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wickens. The network helps show where Mark Wickens may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Wickens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1818 |
| 2 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1348 |
| 3 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Hit paper breakdown → | 2006 | 589 |
| 4 | 2011 | 395 | |
| 5 | 2007 | 383 | |
| 6 | 1995 | 104 | |
| 7 | 2009 | 51 | |
| 8 | 2000 | 35 | |
| 9 | Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. | 2001 | 30 |
| 10 | 2010 | 29 | |
| 11 | PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS | 2010 | 22 |
| 12 | 2006 | 21 | |
| 13 | Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease | 2006 | 2 |
| 14 | 2007 | 1 |
About Mark Wickens
Mark Wickens is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine, Oncology, Organic Chemistry and Molecular Biology, having authored 14 papers that have together received 4.8k indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (4 papers), PARP inhibition in cancer therapy (4 papers), Inflammatory mediators and NSAID effects (3 papers), Pharmacology and Obesity Treatment (2 papers), Venous Thromboembolism Diagnosis and Management (1 paper), Lung Cancer Research Studies (1 paper), Synthesis of β-Lactam Compounds (1 paper) and Eicosanoids and Hypertension Pharmacology (1 paper). The work is most often cited by research in Oncology (2.6k citations), Internal Medicine (286 citations), Reproductive Medicine (493 citations), Cardiology and Cardiovascular Medicine (985 citations) and Cancer Research (658 citations). Mark Wickens has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Michael Friedländer, James Carmichael, Jeffrey N. Weitzel, M. William Audeh, Rita K. Schmutzler, Andrew Tutt, Ursula A. Matulonis, Katherine M. Bell‐McGuinn, Steen Husted and Håkan Emanuelsson. Their work appears in journals such as European Heart Journal, The Lancet, British Journal of Clinical Pharmacology, Journal of the American College of Cardiology and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.